(3-chloro-phenyl)-(1H-imidazol-2-ylmethyl)-amine | 660405-04-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (3-chloro-phenyl)-(1H-imidazol-2-ylmethyl)-amine
• 英文别名: 3-chloro-N-(1H-imidazol-2-ylmethyl)aniline
• CAS: 660405-04-9
• 化学式: C₁₀H₁₀ClN₃
• 分子量: 207.662
• InChiKey: KWRNCEDVXKEPDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-chloro-phenyl)-(1H-imidazol-2-ylmethyl)-amine 在 盐酸 、 水 、 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 19.0h， 生成 (3-chlorophenyl)((1H-imidazol-2-yl)methyl)isopropylamine
  参考文献：
  名称：

  Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012

  摘要：

  A series of imidazole compounds has been identified which affords potent and selective partial and full agonists of the TAAR1 receptor. Starting from 2-benzyl-imidazoline screening hits, a series of structurally related 2-benzyl- and 4-benzyl-imidazoles was investigated first, but it proved highly challenging to obtain compounds having sufficient selectivity against the adrenergic alpha 2 receptor. This issue could be successfully addressed by modification of the linker region and SAR exploration led to the discovery of highly selective isopropyl-substituted 4-aminomethyl-imidazole compounds. The work culminated in the identification of the selective TAAR1 partial agonist RO5073012 (4-chlorophenyl)-(1H-imidazol-4-ylmethyl)-isopropyl-amine, 24), which has a good pharmacokinetic profile after oral administration in rodents. RO5073012 has been found to be active in a behavioural rat model which is considered indicative for schizophrenia. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.060
• 作为产物：
  描述：

  3-氯苯胺 、 2-咪唑甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 (3-chloro-phenyl)-(1H-imidazol-2-ylmethyl)-amine
  参考文献：
  名称：

  Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012

  摘要：

  A series of imidazole compounds has been identified which affords potent and selective partial and full agonists of the TAAR1 receptor. Starting from 2-benzyl-imidazoline screening hits, a series of structurally related 2-benzyl- and 4-benzyl-imidazoles was investigated first, but it proved highly challenging to obtain compounds having sufficient selectivity against the adrenergic alpha 2 receptor. This issue could be successfully addressed by modification of the linker region and SAR exploration led to the discovery of highly selective isopropyl-substituted 4-aminomethyl-imidazole compounds. The work culminated in the identification of the selective TAAR1 partial agonist RO5073012 (4-chlorophenyl)-(1H-imidazol-4-ylmethyl)-isopropyl-amine, 24), which has a good pharmacokinetic profile after oral administration in rodents. RO5073012 has been found to be active in a behavioural rat model which is considered indicative for schizophrenia. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.060

文献信息

• AMINOMETHYL-2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080096906A1

  公开（公告）日：2008-04-24

  The present invention relates to compounds of formula I wherein R 1 is selected from the group consisting of hydrogen or lower alkyl; R 2 is hydrogen, lower alkyl, lower alkenyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, —(CH 2 ) x —S-lower alkyl, —(CH 2 ) x —O-lower alkyl, —(CH 2 ) x —NHC(O)O-lower alkyl, —(CH 2 ) x -aryl, and —(CH 2 ) x -heteroaryl; each R 3 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, lower alkyl substituted by halogen, —O—(CH 2 ) m -aryl, —O—(CH 2 ) m -heteroaryl, —(CR 2 ) m -aryl, and —(CR 2 ) m -heteroaryl; each R is selected from the group consisting of hydrogen, lower alkyl and hydroxy; Ar is selected from the group consisting of phenyl, pyrimidin-2-yl, pyrimidin-4-yl and pyridin-3-yl; n is 0, 1 or 2; x is 0, 1, 2 or 3; m is 0 or 1; and to their pharmaceutically active salts.

  本发明涉及以下式I的化合物 其中 R1选择自羟基或较低烷基; R2为氢、较低烷基、较低烯基、被羟基取代的较低烷基、被卤素取代的较低烷基、—(CH2)x—S-较低烷基、—( )x—O-较低烷基、—( )x—NHC(O)O-较低烷基、—( )x-芳基和—( )x-杂环基中的一种; 每个R3选择自氢、较低烷基、较低烷氧基、卤素、羟基、被卤素取代的较低烷基、—O—( )m-芳基、—O—( )m-杂环基、—(CR2)m-芳基和—(CR2)m-杂环基中的一种; 每个R选择自氢、较低烷基和羟基; Ar选择自苯基、嘧啶-2-基、嘧啶-4-基和吡啶-3-基; n为0、1或2; x为0、1、2或3; m为0或1; 以及其药用活性盐。
• [EN] BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE BENZOPYRANE SUBSTITUES PAR DES AMINES SECONDAIRES DONT IMIDAZOLE, PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：KOREA RES INST CHEM TECH

  公开号：WO2004014898A1

  公开（公告）日：2004-02-19

  The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs.

  本发明涉及取代了次级胺（包括咪唑）的苯并吡喃衍生物，以及其制备方法和含有它们的药物组合物。本发明在药理学上可用于治疗癌症、类风湿性关节炎和糖尿病视网膜病变，通过抗血管生成的特性，同时在保护心脏和神经细胞免受缺血再灌注损伤或保存器官方面也具有药理学上的用途。
• Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them
  申请人：Yi Yang Kyu

  公开号：US20050267188A1

  公开（公告）日：2005-12-01

  The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs.

  本发明涉及用次生胺包括咪唑取代的苯并吡喃衍生物、它们的制备以及包含它们的药物组合物。本发明在药理学上对于通过抗血管生成的性质治疗癌症、类风湿性关节炎和糖尿病视网膜病变非常有用，同时在保护心脏和神经细胞免受缺血再灌注损伤或保护器官方面也具有药理学上的用途。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION
  申请人：Yi Kyu-Yang

  公开号：US20140018402A1

  公开（公告）日：2014-01-16

  The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

  本发明提供了一种用于预防或治疗黄斑退化的药物组合物，其包括以含有咪唑等次生胺的苯并吡喃衍生物或其药学上可接受的盐为活性成分。本发明的药物组合物可以以眼药水的形式使用。
• Pharmaceutical composition for preventing or treating macular degeneration
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US10485786B2

  公开（公告）日：2019-11-26

  The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

  本发明提供了一种用于预防或治疗黄斑变性的药物组合物，其活性成分包括被包括咪唑在内的仲胺取代的苯并吡喃衍生物或其药学上可接受的盐类。本发明的药物组合物可以滴眼液的形式使用。